中國再生醫學(08158.HK):年度淨虧收窄66.1%至4.05億港元
格隆匯3月31日丨中國再生醫學(08158.HK)公佈未經審核全年業績,截至2019年12月31日止年度,實現收益4797.1萬港元,同比下降34.24%;毛利2891.9萬港元,同比增長7.08%;公司擁有人應占本年度虧損4.05億港元,同比收窄66.1%;基本每股虧損0.460港元,不派息。
截至2019年12月31日止年度,集團繼續秉持着“為未來,創再生”及“雙核雙翼,協同發展”的宗旨,集團繼續打造中國“互聯網+再生醫學”的創新產業模式,建立以生物資源儲存為基礎、基因檢測和疾病篩查為依據、組織工程產品為工具、大健康和大醫美為措施、大數據和人工智能為載體、科學研究中心為保障的,集“產、學、研、醫”為一體的中國生物醫藥和大健康產業平台。集團強化各項管理制度,繼續通過運營管理、營銷管理、財務管理、人力資源管理及技術管理五條管控主線的有效推進,持續提升企業經營管理水平。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.